| Medical Guidelines | Reason for Update |
|---|---|
| Biochemical Markers of Alzheimer Disease and Dementia AHS - G2048 | Deleted code 0346U to Billing/Coding section. |
| Biomarker Testing for Autoimmune Rheumatic Disease AHS - G2022 | Updated Billing/Coding section to remove PLA code 0456U, effective 1/1/2025. |
| Diagnosis of Idiopathic Environmental Intolerance AHS - G2056 | Reviewed by Avalon 4th Quarter 2024 CAB. Description, Policy Guidelines and References updated. No change to policy statement. Medical Director review 1/2025 |
| Diagnostic Testing of Sexually Transmitted Infections AHS - G2157 | Added the following code to the Billing/Coding section: 87626. |
| Genetic Testing for Lipoprotein A Variant(s) as a Decision Aid for Aspirin Treatment and/or CVD Risk Assessment AHS – M2082 | Reviewed by Avalon 4th Quarter 2024 CAB. Description, Policy Guidelines, and References updated. No change to policy statement. Medical Director review 1/2025. |
| Genetic Testing for Rett Syndrome AHS – M2088 | Reviewed by Avalon 4th Quarter 2024 CAB. Description, Policy Guidelines and References sections updated. No change to policy statement. Medical Director review 1/2025 |
| Immune Cell Function Assay for Organ Transplant Rejection AHS - G2098 | Reviewed by Avalon 4th Quarter 2024 CAB. Medical Director review 12/2024. Updated policy guidelines and added references. No change to policy statement. |
| Immunohistochemistry AHS – P2018 | Reviewed by Avalon 4th Quarter 2024 CAB. Medical Director Review 1/2025. Policy Guidelines and References updates. No change to policy statement. |
| Oral Cancer Screening and Testing AHS - G2113 | Updated Billing/Coding section to add CPT code 87626, effective 1/1/2025. |
| Pancreatic Cancer Risk Testing Using Pancreatic Cyst Fluid AHS - M2114 | Reviewed by Avalon 4th Quarter 2024 CAB. Medical Director review 12/2024. Updated description, policy guidelines, and guideline recommendations. Added references. No change to policy statement. |
| Pathogen Panel Testing AHS - G2149 | Reviewed by Avalon 4th Quarter CAB 2024 for code updates only. Added codes 0202U, 0223U and 0225U to Billing/Coding section. |
| Pharmacogenetics Testing AHS - M2021 | Reviewed by Avalon 4th Quarter 2024 CAB for code updates only. Code 0380U deleted from Billing/Coding section, effective 1/1/25. |
| Prenatal Testing for Fetal Aneuploidy AHS - G2055 | Reviewed by Avalon 4th Quarter 2024 CAB. Description, related policies, policy guidelines, and references updated. No change to policy statement. Medical Director review 1/2025. |
| Professional Pathology Billing Requirements AHS – R2169 | Removed reimbursement disclaimer and added medical policy disclaimer information. No change to policy statement. |
| Testing for 5-Fluorouracil Use in Cancer Patients AHS - M2067 | Reviewed by Avalon 4th Quarter 2024 CAB. Medical Director review 12/2024. Updated policy guidelines and references. No change to policy statement. |
| Testing for Vector-Borne Infections AHS – G2158 | Added the following codes to the Billing/Coding section: 87164 and 87166. |
| Testosterone AHS – G2013 | Reviewed by Avalon 4th Quarter 2024 CAB. Policy Guidelines and References updated. No changes to coverage criteria. Medical Director review 12/2024 |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.